Clearside Biomedical, Inc. (CLSD)
Largest Insider Buys in Sector
CLSD Stock Price History Chart
CLSD Stock Performance
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. …
Insider Activity of Clearside Biomedical, Inc.
Over the last 12 months, insiders at Clearside Biomedical, Inc. have bought $849,309 and sold $39,372 worth of Clearside Biomedical, Inc. stock.
On average, over the past 5 years, insiders at Clearside Biomedical, Inc. have bought $611,175 and sold $697,766 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WHITMORE BRADFORD T (10 percent owner) — $1.2M. Gibney Anthony S (director) — $129,665. Chong Ngai Hang Victor (CHIEF MEDICAL OFFICER) — $109,410.
The last purchase of 36,500 shares for transaction amount of $36,500 was made by Chong Ngai Hang Victor (Chief Medical Officer) on 2024‑11‑01.
List of Insider Buy and Sell Transactions, Clearside Biomedical, Inc.
| 2024-11-01 | Chief Medical Officer | 36,500 0.0483% | $1.00 | $36,500 | +2.97% | |||
| 2024-06-24 | Chief Medical Officer | 23,500 0.0309% | $1.06 | $24,910 | +0.46% | |||
| 2024-05-15 | director | 7,813 0.0104% | $1.31 | $10,235 | -14.77% | |||
| 2024-04-18 | director | 93,290 0.123% | $1.30 | $121,277 | -12.78% | |||
| 2024-04-17 | director | 6,710 0.0089% | $1.25 | $8,388 | -6.80% | |||
| 2024-03-20 | CHIEF MEDICAL OFFICER | 30,000 0.0394% | $1.60 | $48,000 | -26.38% | |||
| 2024-02-07 | 10 percent owner | 444,444 0.7241% | $1.35 | $599,999 | -9.42% | |||
| 2024-01-19 | Sale | CEO | 18,000 0.0286% | $1.27 | $22,860 | -2.34% | ||
| 2024-01-19 | Sale | Chief Financial Officer | 12,900 0.0207% | $1.28 | $16,512 | -2.34% | ||
| 2023-11-01 | 10 percent owner | 64,366 0.101% | $0.74 | $47,901 | +63.83% | |||
| 2023-10-31 | 10 percent owner | 70,812 0.1147% | $0.73 | $51,537 | +72.51% | |||
| 2023-10-30 | 10 percent owner | 600 0.001% | $0.69 | $411 | +81.42% | |||
| 2023-10-03 | director | 10,000 0.0159% | $0.86 | $8,600 | +44.88% | |||
| 2023-09-25 | director | 10,000 0.0163% | $0.86 | $8,600 | +43.53% | |||
| 2023-01-20 | Sale | Chief Medical Officer | 13,700 0.0223% | $1.47 | $20,139 | -28.67% | ||
| 2023-01-19 | Sale | CEO | 20,030 0.033% | $1.46 | $29,244 | -27.21% | ||
| 2023-01-19 | Sale | Chief Financial Officer | 14,030 0.0238% | $1.50 | $21,045 | -27.21% | ||
| 2023-01-10 | Sale | Chief Medical Officer | 2,170 0.0035% | $1.62 | $3,515 | -35.54% | ||
| 2022-12-21 | director | 14,000 0.0236% | $1.02 | $14,266 | +7.00% | |||
| 2022-11-17 | director | 30,000 0.0489% | $1.33 | $39,900 | -18.52% |
Insider Historical Profitability
| WHITMORE BRADFORD T | 10 percent owner | 4495034 5.9267% | $0.93 | 11 | 3 | +79.94% |
| LASEZKAY GEORGE M | CEO | 466577 0.6152% | $0.93 | 1 | 11 | +58.62% |
| Deignan Charles A. | Chief Financial Officer | 384662 0.5072% | $0.93 | 4 | 7 | +20.35% |
| Gibney Anthony S | director | 100000 0.1319% | $0.93 | 2 | 0 | |
| Chong Ngai Hang Victor | Chief Medical Officer | 100000 0.1319% | $0.93 | 3 | 0 |
Institutional Investor Ownership
| Armistice Capital Llc | $6.05M | 5.29 | 3.96M | New | +$6.05M | 0.02 | |
| The Vanguard Group | $3.81M | 3.33 | 2.49M | +14.45% | +$481,154.41 | <0.0001 | |
| Carmignac | $3.26M | 2.85 | 2.13M | 0% | +$0 | 0.05 | |
| BlackRock | $1.16M | 1.02 | 758,226 | -0.2% | -$2,321.01 | <0.0001 | |
| Geode Capital Management | $982,799.00 | 0.86 | 642,213 | +30.88% | +$231,880.47 | <0.0001 |